<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35898346</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2022.06.21.22276660</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2022.06.21.22276660</ELocationID><Abstract><AbstractText Label="UNLABELLED">The presence and reactivation of chronic viral infections such as Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human immunodeficiency virus (HIV) have been proposed as potential contributors to Long COVID (LC), but studies in well-characterized post-acute cohorts of individuals with COVID-19 over a longer time course consistent with current case definitions of LC are limited. In a cohort of 280 adults with prior SARS-CoV-2 infection, we observed that LC symptoms such as fatigue and neurocognitive dysfunction at a median of 4 months following initial diagnosis were independently associated with serological evidence of recent EBV reactivation (early antigen-D [EA-D] IgG positivity) or high nuclear antigen IgG levels, but not with ongoing EBV viremia. Evidence of EBV reactivation (EA-D IgG) was most strongly associated with fatigue (OR 2.12). Underlying HIV infection was also independently associated with neurocognitive LC (OR 2.5). Interestingly, participants who had serologic evidence of prior CMV infection were less likely to develop neurocognitive LC (OR 0.52) and tended to have less severe (&gt;5 symptoms reported) LC (OR 0.44). Overall, these findings suggest differential effects of chronic viral co-infections on the likelihood of developing LC and predicted distinct syndromic patterns. Further assessment during the acute phase of COVID-19 is warranted.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">The authors found that Long COVID symptoms in a post-acute cohort were associated with serological evidence of recent EBV reactivation and pre-existing HIV infection when adjusted for participant factors, sample timing, comorbid conditions and prior hospitalization, whereas underlying CMV infection was associated with a decreased risk of Long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deveau</LastName><ForeName>Tyler-Marie</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryder</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buck</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck-Engeser</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Fay</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Viva</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Leonel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Nikita S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deswal</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngo</LastName><ForeName>Lynn H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buitrago</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jessica Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Brandon C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chenna</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winslow</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petropoulos</LastName><ForeName>Christos J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deitchman</LastName><ForeName>Amelia N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of California, San Francisco CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellmuth</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscilla Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI158013</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI145806</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167648</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>J Clin Invest. 2023 Feb 1;133(3):e163669. doi: 10.1172/JCI163669</RefSource><PMID Version="1">36454631</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35898346</ArticleId><ArticleId IdType="pmc">PMC9327632</ArticleId><ArticleId IdType="doi">10.1101/2022.06.21.22276660</ArticleId><ArticleId IdType="pii">2022.06.21.22276660</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. [published online ahead of print: March 22, 2021]; doi:10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>A clinical case definition of post COVID-19 condition by a Delphi consensus, 6
October
20212021;https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.
cited
June 16, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. [published online ahead of print: September 27, 2021]; doi:10.1093/infdis/jiab490</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20(1):172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, et al. The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat. Neurosci. 2021;1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553622</ArticleId><ArticleId IdType="pubmed">34675436</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell 2022;0(0). doi:10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin. Infect. Dis. [published online ahead of print: July 5, 2021]; doi:10.1093/cid/ciab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, et al. Evolution of antibody immunity to SARS-CoV-2. Nature [published online ahead of print: January 18, 2021]; doi:10.1038/s41586-021-03207-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow D, et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Research Square 2021; doi:10.21203/rs.3.rs-1139035/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1139035/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y) [published online ahead of print: April 13, 2022]; doi:10.1016/j.medj.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, et al. Post-acute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology [published online ahead of print: April 28, 2022]; doi:10.1053/j.gastro.2022.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller MC, et al. A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings. Ann. Intern. Med. [published online ahead of print: May 24, 2022]; doi:10.7326/M21-4905</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4905</ArticleId><ArticleId IdType="pmc">PMC9128805</ArticleId><ArticleId IdType="pubmed">35605238</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Lack of Antinuclear Antibodies in Convalescent COVID-19 Patients with Persistent Symptoms. Clin. Infect. Dis. [published online ahead of print: October 7, 2021]; doi:10.1093/cid/ciab890</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab890</ArticleId><ArticleId IdType="pmc">PMC9187313</ArticleId><ArticleId IdType="pubmed">34617982</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43(4):268&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunmire SK, Verghese PS, Balfour HH Jr. Primary Epstein-Barr virus infection. J. Clin. Virol. 2018;102:84&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525635</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp JM. Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease. Curr. Top. Microbiol. Immunol. 2015;391:289&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">26428379</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, et al. Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels. Oral Oncol. 2019;93:85&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">31109701</ArticleId></ArticleIdList></Reference><Reference><Citation>Fechtner S, et al. Antibody Responses to Epstein-Barr Virus in the Preclinical Period of Rheumatoid Arthritis Suggest the Presence of Increased Viral Reactivation Cycles. Arthritis Rheumatol 2022;74(4):597&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957485</ArticleId><ArticleId IdType="pubmed">34605217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022;375(6578):296&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloisi F, Salvetti M. Epstein-Barr virus and multiple sclerosis: supporting causality. Lancet Neurol. 2022;21(4):300&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">35305331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, et al. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci. Rep. 2021;11(1):10902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S, et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int. J. Infect. Dis. 2021;104:315&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now 2021;51(3):296&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehner GF, et al. Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19. Crit. Care 2020;24(1):657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682685</ArticleId><ArticleId IdType="pubmed">33228750</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, et al. SARS-CoV-2 respiratory co-infections: Incidence of viral and bacterial co-pathogens. Int. J. Infect. Dis. 2021;105:617&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905386</ArticleId><ArticleId IdType="pubmed">33640570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, et al. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens 2021;10(6). doi:10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Klutts JS, et al. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J. Clin. Microbiol. 2009;47(10):3204&#x2013;3210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756947</ArticleId><ArticleId IdType="pubmed">19656988</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber S, et al. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. PLoS One 2022;17(5):e0268530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132318</ArticleId><ArticleId IdType="pubmed">35613127</ArticleId></ArticleIdList></Reference><Reference><Citation>Alanio C, et al. Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization. J. Infect. Dis. [published online ahead of print: February 2, 2022]; doi:10.1093/infdis/jiac020</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac020</ArticleId><ArticleId IdType="pmc">PMC8905965</ArticleId><ArticleId IdType="pubmed">35134186</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Post-acute sequelae and adaptive immune responses in people living with HIV recovering from SARS-CoV-2 infection. bioRxiv 2022; doi:10.1101/2022.02.10.22270471</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.10.22270471</ArticleId><ArticleId IdType="pmc">PMC9444925</ArticleId><ArticleId IdType="pubmed">35866847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingery JR, et al. Health Status, Persistent Symptoms, and Effort Intolerance One Year After Acute COVID-19 Infection. J. Gen. Intern. Med. 2022;37(5):1218&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786200</ArticleId><ArticleId IdType="pubmed">35075531</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. Neurol Neuroimmunol Neuroinflamm 2022;9(5). doi:10.1212/NXI.0000000000200003</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, et al. Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight [published online ahead of print: April 7, 2022]; doi:10.1172/jci.insight.157053</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.157053</ArticleId><ArticleId IdType="pmc">PMC9220849</ArticleId><ArticleId IdType="pubmed">35389890</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman D, et al. Cytomegalovirus infection enhances the immune response to influenza. Sci. Transl. Med. 2015;7(281):281ra43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505610</ArticleId><ArticleId IdType="pubmed">25834109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikby A, et al. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp. Gerontol. 2002;37(2&#x2013;3):445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">11772532</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole E, et al. Human Cytomegalovirus Interleukin 10 Homologs: Facing the Immune System. Front. Cell. Infect. Microbiol. 2020;10:245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296156</ArticleId><ArticleId IdType="pubmed">32582563</ArticleId></ArticleIdList></Reference><Reference><Citation>Apple AC, et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol 2022;9(2):221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862406</ArticleId><ArticleId IdType="pubmed">35043593</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcendor DJ, et al. Infection and upregulation of proinflammatory cytokines in human brain vascular pericytes by human cytomegalovirus. J. Neuroinflammation 2012;9:95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413582</ArticleId><ArticleId IdType="pubmed">22607552</ArticleId></ArticleIdList></Reference><Reference><Citation>Shnayder M, et al. Defining the Transcriptional Landscape during Cytomegalovirus Latency with Single-Cell RNA Sequencing. MBio 2018;9(2). doi:10.1128/mBio.00013-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00013-18</ArticleId><ArticleId IdType="pmc">PMC5850328</ArticleId><ArticleId IdType="pubmed">29535194</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?. QJM 2022;114(12):865&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng LN, et al. Case report of breakthrough long COVID and the use of nirmatrelvir-ritonavir 2022; doi:10.21203/rs.3.rs-1443341/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1443341/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M, et al. Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies. Pathogens and Immunity 2022;7(1). doi:10.20411/pai.v7i1.518</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v7i1.518</ArticleId><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Persistence, Magnitude and Patterns of Post-acute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infect Dis [published online ahead of print: December 21, 2021]; doi:10.1093/ofid/ofab640</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab640</ArticleId><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Symptoms of COVID-19. Centers for Disease Control and Prevention
2022;https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
cited
July 14, 2022</Citation></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom. Med. 2002;64(2):258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914441</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;109518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Staras SAS, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988&#x2013;1994. Clin. Infect. Dis. 2006;43(9):1143&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029132</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Plasma markers of neurologic injury and systemic inflammation in individuals with self-reported neurologic post-acute sequelae of SARS-CoV-2 infection (PASC). bioRxiv 2021; doi:10.1101/2021.11.02.21265778</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.02.21265778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>